Data: 08/08/2026
Total encontrado: 35
1/35US=324 / Tese/FAP
Marques EF. Avaliação da família do receptor de fator de crescimento epidérmico no carcinoma gástrico. [Evaluation of epidermal growth factor receptor family in gastric cancer]. São Paulo, 2010. 74 p. Dissertação(Mestrado)-Fundação Antônio Prudente.

Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2010/EmyFukuda/EmyFukuda.pdf

Curriculum Lattes

RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR ERBB-2; GENE EGFR; CANCER DE ESTOMAGO; IMUNOISTOQUIMICA; HIBRIDIZACAO IN SITU POR FLUORESCENCIA


2/35US=18 / Pélvis
El-Shami K, Nallapareddy S, Messersmith W. Systemic therapy for colon cancer. In: Gearhart SL, Ahuja N. Colorectal cancer. Philadelphia: Elsevier Saunders, 2011. p. 167-83. (Early Diagnosis and Treatment of Cancer) ISBN 978-1-4160-4686-8.

CANCER COLORRETAL; CANCER DE COLON. TERAPIA SISTEMICA; CANCER COLORRETAL METASTATICO; 5-FLUOROURACIL; LEUCOVORIN; IRINOTECAN; OXALIPLATINA; FOLFOX; FOLFIRI; FLUOROPIRIMIDINAS ORAIS; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; BEVACIZUMAB; ANGIOGENESE; TERAPIA SISTEMICA ADJUVANTE


3/35US=3 / Gastro
Khandekar JD, Khandekar M. Systemic therapy for gastric cancer. In: Gore RM. Gastric cancer. New York: Cambridge University Press, 2010. p. 98-119. (Contemporary issues in cancer imaging) ISBN 978-0-521-51383-8.

CANCER GASTRICO; TERAPIA SISTEMICA; QUIMIOTERAPIA SISTEMICA; COMBINACAO QUIMIOTERAPICA; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; QUIMIOTERAPIA NEOADJUVANTE; IMUNOQUIMIOTERAPIA


4/35US=4 / Cirurgia
Charles AJ, Roy V, Perez EA. Adjuvant therapy in breast cancer. In: Silberman H, Silberman AW. Principles and practice of surgical oncology: a multidisciplinary approach to difficult problems. Philadelphia: J B Lippincott, 2010. p. 397-418. ISBN 978-0-7817-6546-6.

CANCER; ONCOLOGIA CIRURGICA; CANCER DE MAMA. TERAPIA ADJUVANTE; ANALISE DE EXPRESSAO GENICA; QUIMIOTERAPIA ADJUVANTE; TAXANOS; QUIMIOTERAPIA ADJUVANTE POS-MENOPAUSA; TERAPIA METRONOMICA; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO HUMANO 2; TRASTUZUMAB; MANIPULACAO HORMONAL ADJUVANTE


5/35US=32 / Gastro
Huitzil-Melendez FD, Abou-Alfa GK, Morse MA. Novel therapies targeted at sinal transduction in liver tumors. In: Clavien PA, Breitenstein S. Malignant liver tumors: current and emerging therapies. 3ª ed. New Jersey: John Wiley & Sons, 2010. p. 382-92. ISBN 978-1-4051-7976-8.

CANCER DE FIGADO; TRANSDUCAO DE SINAL; RECEPTORES TIROSINA QUINASE (RTK); RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO INSULIN-LIKE (IGF-I); PROTO-ONCOGENE C-MET; VIAS INTRACELULARES DE TRANSDUCAO DE SINAL; MAPK; PI3K; AKT; MTOR; FAMILIA RAS; WNT/B-CATENIN; ANGIOGENESE


6/35US=26-A / Radioterapia
Ang KK, O'Reilly MS, Meyn RE Jr, Milas L. Principles of combining radiation therapy and molecular therapeutics. In: Cox JD, Ang KK. Radiation oncology: rationale, technique, results. 9ª ed. Philadelphia: Elsevier Mosby, 2010. p. 118-37. ISBN 978-0-323-04971-9.

RADIOTERAPIA; TRATAMENTO DO CANCER; TERAPIA MOLECULAR; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; ANGIOGENESE; AGENTES ANTIANGIOGENICOS; CICLOOXIGENASE; VIA DE SINALIZACAO RAS; TERAPIA GENICA; IMUNOTERAPIA


7/35US=3 / Radioterapia
Wheeler DL, Hoang T, Harari PM. Contributions of targeted agents. In: Harari PM, Connor NP, Grau C. Functional preservation and quality of life in head and neck radiotherapy. New York: Springer, 2009. p. 215-23. (Medical radiology/Radiation oncology) ISBN 978-3-540-73231-0.

AGENTES ALVO; CABECA E PESCOCO; CARCINOMA DE CELULAS ESCAMOSAS; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; FATOR DE CRESCIMENTO VASCULAR ENDOTELIAL (VEGF); BEVACIZUMABE; TOXICIDADE; QUALIDADE DE VIDA


8/35US=15 / Biol/Mol
Bourguignon LYW. Hyaluronan-mediated CD44 interaction with receptor and non-receptor kinases promotes oncogenic signaling, cytoskeleton activation and tumor progression. In: Stern R. Hyaluronan in cancer biology. Amsterdam: Elsevier, 2009. p. 89-107. ISBN 978-0-12-374178-3.

CANCER; ACIDO HIALURONICO; CD44; HER2; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; EGFR; TGFBETA


9/35US=16 / Estatística
Xu XC. Risk factors and gene expression in esophageal cancer. In: Verma M. Cancer epidemiology. New York: Humana Press, 2009. p. 335-60. (Methods in Molecular Biology, 471) ISBN 978-1-58829-987-1.

CANCER DE ESOFAGO; FATORES DE RISCO; EXPRESSAO GENICA; TABAGISMO; ALCOOLISMO; REFLUXO GASTROESOFAGICO; ALTERACOES GENETICAS; CANCER. PREVENCAO; ESOFAGO DE BARRET; ADENOCARCINOMA ESOFAGICO; MUTACAO DO GENE P53; ALTERACAO DO GENE P16; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMAL (EGFR); CADERINA-E; COX-2; QUIMIOPREVENCAO; ACIDOS RETINOICOS; ANTI-INFLAMATORIOS NAO ESTEROIDES; EGCG; CURCUMINA


10/35US=35 / Gastro
Kiguchi K, DiGiovanni J. Role of growth factor-signaling pathways. In: Thomas CR Junior, Fuller CD. Biliary tract and gallbladder cancer: diagnosis and therapy. New Jersey: DemosMedical, 2009. p. 19-34. ISBN 978-1-933864-42-6.

NEOPLASIAS DO TRATO BILIAR; CANCER DE VESICULA BILIAR; FATOR DE CRESCIMENTO; FAMILIA ERBB; RECEPTOR DO FATOR DE CRESCIMENTO INSULIN-LIKE 1; C-MET; MTOR; COX-2


11/35US=50 / Câncer
Berz D, McCormack E, Mega A, Wanebo HJ. Targeting signaling pathways in cancer therapy. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 309-26. ISBN 978-1-60327-086-1.

EGFR; RECEPTOR DO FATOR DE CRESCIMENTO EPITELIAL; INIBIDORES DA QUINASE DE TIROSINA; MOLECULAS PEQUENAS; SOLIDAS MALIGNAS DE TUMORES; TERAPIA-ALVO; PREDITORES DE RESPOSTA; CANCER DE MAMA; CARCINOMA HEPATOCELULAR; CANCER DE PULMAO; CANCER DE COLON


12/35US=50 / Câncer
Karrim J, Dubey S. Advances in the treatment of lung cancer. In: Leong SPL, editor. From local invasion to metastatic cancer: involvement of distant sites through the lymphovascular system. New York: Humana Press, 2009. p. 545-52. ISBN 978-1-60327-086-1.

TRATAMENTO DO CANCER DO PULMAO; NEOPLASIAS PULMONARES; QUIMIOTERAPIA; ADJUVANTE; MARCADORES BIOLOGICOS; ANGIOGENESE; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INIBIDORES DA PROTEINA QUINASE; ANTICORPOS MONOCLONAIS; RADIOTERAPIA


13/35US=89 / Biol/Mol
Kang C, Pu P, Jiang H. Silencing epidermal growth factor receptor by RNA interference in glioma. In: Walther W, Stein US. Gene therapy of cancer: methods and protocols. 2ª ed. New Jersey: Humana Press, 2009. p. 335-49. (Methods in Molecular Biology, 542) ISBN 978-1-59745-561-9.

RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; INTERFERENCIA DE RNA; GLIOMA; EGFR; INVASAO; PROLIFERACAO; SIRNA


14/35US=96 / Biol/Mol
Márquez-Garbán DC, Chen HW, Goodglick L, Fishbein MC, Pietras RJ. Targeting aromatase and estrogen signaling in human non-small cell lung cancer. In: Bradlow KL, Carruba G. Steroid enzymes and cancer. Boston: Blackwell, 2009. p. 194-205. (Annals of the New York Academy of Science,v.155) ISBN 9978-1-57331-745-0.

NSCLC; CYP19; EGFR; NAO-PEQUENAS CELULAS DE PULMAO; AROMATASE; RECEPTOR DE ESTROGENO; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DO FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; ANASTRAZOLE; EXEMESTANO; FULVESTRANT; VANDETANIB


15/35US=96 / Biol/Mol
Berasain C, Castillo J, Perugorria MJ, Latasa MU, Pietro J, Avila MA. Inflammation and liver cancer. In: Bradlow KL, Carruba G. Steroid enzymes and cancer. Boston: Blackwell, 2009. p. 206-21. (Annals of the New York Academy of Science,v.155) ISBN 9978-1-57331-745-0.

CARCINOMA HEPATOCELULAR; INFLAMACAO; FATOR NUCLEAR-&*1181;B; NF-&*1181;B; STAT3; IL-6; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; AMPHIREGULIN; TOLL-LIKE RECEPTOR; TLR; RECONHECIMENTO DE RECEPTORES PADRAO; PRRS


16/35US=9-A / Ginecologia
Dorigo O, Mertínez-Maza O, Berek JS. Biologic, targeted, and immune therapies. In: Berek JS, Hacker NF. Berek and Hacker's gynecologic oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2009. p. 41-56. ISBN 978-0-7817-9512-8.

ONCOLOGIA GINECOLOGICA; TERAPIAS BIOLOGICA; IMUNOTERAPIA; ANGIOGENESE; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; INIBIDORES DO RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; HER-2/NEU; COMPONENTES DO SISTEMA IMUNOLOGICO


17/35US=23-A / Câncer
Bartolazzi A. Non-small cell lung carcinoma: EGFR gene mutations and response to gefitinib. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods and overviews, lung carcinoma and prostate carcinoma. v.2. New York: Springer, 2008. p. 291-306. ISBN 978-1-4020-8441-62.

CANCER; CANCER DE PULMAO; CANCER DE PULMAO DE NAO-PEQUENAS CELULAS; MUTACOES EGFR; GEFITINIBE; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO


18/35US=23-A / Câncer
Kiura K, Takigawa N, Segawa Y. Advanced non-small cell lung carcinoma: acquired resistance to gefitinib. In: Hayat MA. Methods of cancer diagnosis, therapy and prognosis: general methods and overviews, lung carcinoma and prostate carcinoma. v.2. New York: Springer, 2008. p. 307-16. ISBN 978-1-4020-8441-62.

CANCER; CANCER DE PULMAO; CANCER DE PULMAO DE NAO-PEQUENAS CELULAS; CARCINOMA NAO PEQUENAS CELULAS DO PULMAO AVANCADA; RESISTENCIA A GEFITINIBE; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO


19/35US=53 / Biol/Mol
Sandberg A, Stone JF. Key mechanisms and pathways. In: ___. The genetics and molecular biology of neural tumors. New Jersey: Humana Press, 2008. p. 431-43. ISBN 978-1-59745-510-7.

TUMORES NEURAIS; VIAS MOLECULARES; TP53; RB; WNT; SHH; EGFR; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; TELOMERES; TELOMERASE; EPIGENETICA; CICLO CELULAR; APOPTOSE


20/35US=90 / Biol/Mol
Lao HJ, Carpenter G. EGFR signaling networks: nuclear ErbB receptors: pathways and functions. In: Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. New Jersey: Humana Press, 2008. p. 187-97. (Cancer Drug Discovery and Development) ISBN 978-1-59745-356-1.

ERBB; FATOR DE CRESCIMENTO EPIDERMICO; RECEPTOR DO FATOR DE CRESCIMENTO EPIDERMICO; NUCLEO; SINALIZAR; TRANSDUCAO


Primeira | Anterior | Próxima | Última